NEOK Bio

[NEOK Bio @NEOKBio]

NEOK is attending several upcoming conferences.

@Oppenheimer, @GoldmanSachs, @Stifel, @Jefferies, & @UBS

Heading to any of these events? Let’s connect!

#Biotech #LifeSciences #HealthcareInnovation

[NEOK Bio @NEOKBio]

NEOK Bio’s CEO, Mayank Gandhi, M.D., recently joined @dslevine on #TheBioReportPodcast to discuss the current challenges, potential, and future of antibody-drug conjugates (ADCs) in the treatment of solid tumors.

Listen here: https://t.co/Fs4T20wwJd

#ADC #MedEd

[NEOK Bio @NEOKBio]

NEOK Bio CEO Mayank Gandhi shares his perspective in @PharmaVoice on reducing delays and accelerating access for clinical trials in the U.S.

Read more: https://t.co/p3jmMTOlbD

#ADC #ClinicalTrials #Biopharma #DrugDevelopment #MedEd

[NEOK Bio @NEOKBio]

NEOK Bio’s CEO, Mayank Gandhi, M.D., recently joined @KarenJagoda on the Empowered Patient Podcast to discuss how bispecific #AntibodyDrugConjugates could address some of the most pressing challenges in solid tumors.
Listen here: https://t.co/ZS9u4fwazS
#ADC #MedEd

[NEOK Bio @NEOKBio]

NEOK Bio has dosed the first patients in Phase 1 trials for NEOK001 and NEOK002, our lead bispecific ADC candidates targeting difficult-to-treat solid tumors.

Read more: https://t.co/CyIkJrHWHp

#ADCs #AntibodyDrugConjugates #CancerResearch #Innovation #Biotech #MedEd

[NEOK Bio @NEOKBio]

NEOK Bio is heading to @CHI_Healthtech's 2026 #PEGSummit! Hear from our CEO, Mayank Gandhi, on the development of our dual‑targeting #BispecificADC strategy.

View the program: https://t.co/RetH6l5eTk

#AntibodyDrugConjugates #OncologyInnovation #Biotech #DrugDevelopment #MedEd

[NEOK Bio @NEOKBio]

We’re excited to present new research at this year’s @AACR Annual Meeting. If you’re going to be at #AACR2026, come see our poster and meet the team!

Learn more: https://t.co/LccGbzD2Xp

#ADC #AntibodyDrugConjugates #CancerResearch #OncologyInnovation #MedEd

[NEOK Bio @NEOKBio]

NEOK Bio is proud to announce the @US_FDA has granted Investigational New Drug (IND) clearance for NEOK002, our Novel Bispecific ADC Targeting EGFR and MUC1 in solid tumors.

Learn more: https://t.co/CUQsR02V3P

#IND #ADC #Oncology

[NEOK Bio @NEOKBio]

#NEWS: The @US_FDA accepted our IND application for NEOK001.

This approval will allow us to start a Phase 1 clinical trial and be our first program to enter clinical development.

Learn more: https://t.co/id1Vw5Lnuz

#IND #ADC #oncology

[NEOK Bio @NEOKBio]

Save the date: Our CEO, Mayank Gandhi, M.D., presents at #BiotechShowcase in San Francisco, Monday, January 12, 2025, at 1:30 p.m. PST!

Connect with us here: https://t.co/xETKEHDeC1

#JPMWeek #Biotech #Leadership

[NEOK Bio @NEOKBio]

We’re at @SachsAssociates 11th Annual Oncology Innovation Forum!

CEO Mayank Gandhi, M.D., joins a panel on Next-Gen ADCs & Bispecifics. Later, NEOK Bio presents our vision for better cancer outcomes.

#Sachs_OIF #Leadership #ADC #Biotech

[NEOK Bio @NEOKBio]

NEOK BIO launches with $75 million financing to pioneer the future of bispecific antibody drug conjugates in hard-to-treat cancers.

Stay tuned for more updates and read the press release here: https://t.co/Q7lccPZ3er

#ADC #drugdevelopment #innovation #oncology #SeriesA